title: The development of next-generation screening and diagnostic platforms will change diabetes care.
abstract: Diabetes mellitus is a common disease with a rising incidence and the findings of hyperglycemia and glucosuria. However, there are multiple types of diabetes, each with distinct etiologies. The two major types of diabetes are type 1, which is caused by an autoimmune process, and type 2, which is thought to be primarily metabolic, resulting from insulin resistance, often in the setting of obesity. Historically, the distinction between these two types was obvious. Here, we discuss how this paradigm has dramatically changed because of both the evolving epidemiology of diabetes mellitus and new and emerging tools, and therapies to diagnose and treat diabetes. As we believe that understanding these changes is critical to providing optimal care to patients with diabetes, we have developed a novel plasmonic gold chip platform that is able to meet the new and emerging demands of modern diabetes care.
authors.affiliation: Department of Pediatrics, Stanford School of Medicine, Stanford University, Stanford, CA, USA.
authors.forename: Rajiv B
authors.initials: RB
authors.lastname: Kumar
authors.forename: Mihir
authors.initials: M
authors.lastname: Gupta
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Feldman
mesh_terms: D003920:Diabetes Mellitus / Q000175:diagnosis* / Q000209:etiology; D019937:Diagnostic Techniques and Procedures / Q000592:standards; D019468:Disease Management; D006801:Humans
keywords: autoantibodies; diabetes; diabetes mellitus; plasmonic gold chip